Exelixis
EXELNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Market cap
$14.624 B
$59.02 +0.99%
Close of 9 Oct 2026
As of 9 Oct 2026, Exelixis (EXEL) has a market capitalization of $14.6B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.
Revenue
$2.32B
#1055 by revenue
Earnings
$782.6M
#468 by earnings
Shares outstanding
247,781,692
Latest filing cover page
P/E ratio
18.7
Cap ÷ net income
Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap
All 160 →- #6BiogenBIIB$32.3B
- #7BioNTech SEBNTX$23.1B
- #8ExelixisEXEL$14.6B
- #9Neurocrine BiosciencesNBIX$14.4B
- #10Halozyme TherapeuticsHALO$12.5B
What if Exelixis were worth as much as…
Open the what-if tool →Where these numbers come from
Share counts and financials for Exelixis are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 10 Oct 2026. Read the methodology.